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Abstract
Background: Persistent residual viremia (RV) and low grade inflammation and immune activation have been
associated with non-AIDS defining events. The impact of persistent RV and HIV-DNA load on immune activation/
inflammation remains unclear. The purpose of this study was to gain new insights into the relation between
viremia, markers of inflammation and HIV-DNA levels.
Methods: Three hundred and twenty-one HIV-infected patients were studied. A retrospective analysis of viremia
values, prospectively collected for 48 months, was performed. Patients were separated into three groups: 113 TND
(Target Not Detected, patients with sustained undetectable viremia); 113 RV (Residual Viremia, patients who had at
least three detectable viral load (VL) values <37 copies/ml); 95 LLV (Low Level Viremia, patients with at least two VL
values >37 but <200 copies/ml). HIV-DNA, TNF-α, IL-6 and sCD14 were analyzed.
Results: HIV-DNA, sCD14 and TNF-α were significantly lower in the TND group than in the RV and LLV groups. In
addition, RV patients showed lower levels of HIV-DNA and sCD14 than LLV individuals. HIV-DNA load was not
related to markers of inflammation. The ordinal logistic analysis showed that two independent variables were
significantly associated with VL pattern: sCD14, HIV-DNA. In addition NRTIs plus NNRTIs and NRTIs plus PIs were
negatively associated to VL pattern compared to INI-containing regimen.
Conclusions: Persistent undetectable viremia was associated with lower levels of inflammatory markers and HIV-
DNA. However, the lack of normalization of these biomarkers in the TND group and the fact that HIV-DNA load was
not associated with inflammation strongly suggest that other mechanisms play a major role in maintaining
inflammation over time.
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Background
Persistent systemic inflammation has been associated with
human HIV disease progression [1, 2]. Antiretroviral ther-
apy (ART) suppresses viral load (VL), but even after long-
term effective treatment HIV-infected individuals have
persistent low grade inflammation and immune activation
that have been associated with a number of serious non-
AIDS defining events [3–7]. Persistent viral replication, re-
sidual immune dysregulation, or microbial translocation
(MT) have been implicated in the mechanism underlying
immune activation in these patients [8–11]. High-
sensitivity C-reactive protein (hsCRP) and interleukins 6
and 10 (IL-6, IL-10) have been associated with low level
HIV viremia and reported as predictors of noninfectious
complications including cardiovascular disease (CVD),
cancer and overall mortality [12–16].
MT can be observed in most untreated HIV-positive
patients and is considered one of the main causes of
chronic inflammation in HIV infection [17, 18].
Lipopolysaccharide (LPS) is considered a major marker
of MT. It has been reported that circulating levels of LPS
are a strong predictor of disease progression independently
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of viral load and CD4+ cell count [17]. LPS stimulation
leads CD14+ monocytes/macrophages to secrete soluble
CD14 (sCD14), which bind to LPS. Wada et al. found that
sCD14 levels were significantly higher in HIV-infected
compared to uninfected individuals, but did not differ be-
tween patients without or with effective ART and changed
very little in the years following ART initiation [19]. Higher
levels of sCD14 as well as tumor necrosis factor alpha
(TNF-α), IL-6 and LPS were found in patients with MT ir-
respective of viremia value. However, HIV-treated patients
with undetectable VL presented MT less frequently than
patients with low level HIV viremia [20].
The impact of persistent residual viremia on immune
activation, inflammation and microbial translocation is
currently unclear. One hypothesis is that despite low
viral concentrations, the ongoing presence of virus could
prevent the normalization of some systemic inflamma-
tory markers. In addition, residual viremia has been cor-
related with the size of the viral reservoirs as measured
by HIV-DNA, indicating a link between these parame-
ters [21–23], whereas HIV-DNA load is not associated
with immune activation [24].
The purpose of this study was to further investigate
the relation between the degree of residual viremia,
HIV-DNA levels and inflammation. A better under-
standing of how these parameters are related could add
information on the mechanism(s) involved in immune
activation and help identify potential preventive inter-
ventions in HIV patients.
Methods
Study population
Three hundred and twenty-one HIV-infected patients
from Umberto I University Hospital were studied. Viremia
values were prospectively collected, for 48 months, as part
of routine clinical practice. The analysis started at an arbi-
trary time point during combination ART (cART), the
first viremia value quantified by kinetic PCR molecular
system (see below) was considered as baseline VL. For this
study we selected patients who had been HIV positive for
a long period of time, showed a long time of treatment
and had achieved viral suppression (HIV RNA <50 copies/
ml in two consecutive VL determination), before the
baseline.
Patients were grouped according to their VL pattern:
group TND (Target Not Detected): patients with a sus-
tained undetectable viremia throughout follow-up
(n = 113); group RV (Residual Viremia): patients who
had at least three detectable VL values but below the
threshold value, during the study period (n = 113); group
LLV (Low Level Viremia): patients with at least two VL
values over the threshold value but below 200 copies/ml
(n = 95). Data were analyzed at the end of the follow-up.
The study was approved by the Ethical Committee of
Sapienza University Hospital (Ethical Committee
authorization number # 07–09-15/3725).
HIV-RNA evaluation
HIV-RNA was quantified using the kinetic PCR molecular
system (kPCR, Versant HIV-RNA kPCR 1.0; Siemens
Healthcare Diagnostics). The kPCR assay gives two pos-
sible outputs: (i) a quantitative result for HIV-RNA values
ranging from ≥37 copies/mL to 11,000,000 copies/mL; (ii)
a qualitative result for HIV-RNA values between 1 and 37
copies/mL (target detected) and an ‘undetectable’ result if
no signal can be detected (target not detected).
Evaluation of inflammation markers: TNF-α, IL-6 and
sCD14
Levels of tumor TNF-α, IL-6 and sCD14 samples, collected
and stored during the follow-up period, were measured
using a commercially available enzyme-linked immuno-
sorbent assay (ELISA) kit (Enzo Life Sciences, Inc. Farming-
dale, NY, USA), according to manufacturer’s instructions.
The lower limit of detection (LOD) was 6 pg/ml for IL-6,
8.4 pg/ml for TNF-α and 1 μg/ml for sCD14.
HIV-DNA evaluation
Blood samples collected in EDTA were separated into
plasma and cells by Ficoll-Hypaque density gradient cen-
trifugation. Dry pellets were stored at −20 °C until used.
Total DNA was extracted from PBMCs using a QIAamp
DNA mini kit (QIAGEN, Hilden, Germany), according
to the manufacturer’s instructions, to obtain 100 μl of
eluate.
Total HIV-DNA was quantified using the “Generic
HIV-DNA Cell” commercial kit (Biocentric, Bandol,
France) according to the manufacturer’s instructions.
Statistical analysis
The quantitative variables were expressed as the median
[interquartile range (IQR)], and the categorical variables
were expressed as absolute and relative frequencies.
χ2 test was used to evaluate percentage differences in
patients between groups. Mann-Whitney with Bonfer-
roni correction and Kruskal-Wallis tests were used to
evaluate differences between CD4 cell, sCD14, inflam-
mation markers and HIV-DNA levels among two or
three groups of patients.
HIV-DNA and plasma levels of sCD14 and IL-6 were
correlated by Spearman correlation test. A regression
model for logistic ordinal dependent variables was built
to identify factors associated with VL (TND, RV, LLV).
The VL pattern was considered an ordinal dependent
variable. The following variables were included in the
model: gender (0 = male, 1 = female); age (years, quanti-
tative); therapy regimen [0 = integrase inhibitors (INI),
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1 = other, 2 = nucleoside reverse transcriptase inhibitors
(NRTIs) + non-nucleoside reverse transcriptase inhibitors
(NNRTIs), 3 = NRTIs + protease inhibitors (PIs)]; duration
of therapy (years, quantitative); stage of disease (0 = A1-A3,
1 = B1-B3, 2 = C1-C3); years from testing (quantitative);
HBV (0 = negative, 1 = positive); HCV (0 = negative,
1 = positive); sCD14 (quantitative); IL-6 (quantitative);
TNF-α (quantitative); HIV-DNA (quantitative).
Results
Characteristics of the study subjects
The study analyzed 321 HIV-infected patients, 217 males
and 104 females, receiving ART. The general characteris-
tics of the patients, collected at 48 months, are summa-
rized in Table 1. The median participant age was 53 years
[IQR 47–58 years] and there was no difference among
study groups in age distribution. The median CD4+ cell
count was 601 cells/mm3 [IQR 382–854 cells/mm3] and
median CD4+ nadir was 222 cells/mm3 [IQR 108–366
cells/mm3]. Median CD4+ cell count was slightly lower in
the RV group compared to the group with undetectable
viremia [565 cells/mm3 (IQR 302–796) vs 641 cells/mm3
(IQR 523–888) p = 0.017). Patients had been on ART for a
median of 15 years (IQR 9–19 years).
Markers of systemic inflammation
Biomarkers of immune activation, TNF-α and IL-6 were
measured in participant’s plasma at the end of follow-up.
There was no difference in the proportion of patients
with TNF-α values above LOD among groups (TND and
RV group: 12.4%; LLV group: 7.1%; p = 0.196). However,
median plasma levels of TNF-α were significantly higher
in the patients with RV [23 pg/ml (IQR 18.2–26.2 pg/
ml)] or LLV [25.6 pg/ml (IQR 22.7–30.1 pg/ml)] than in
the group with undetectable VL [15.5 pg/ml (IQR 13.1–
21.0 pg/ml)] (TND vs RV, p = 0.046; TND vs LLV,
p = 0.02) (Fig. 1a).
Interestingly, more patients in the TND group had IL-
6 levels above LOD when compared with the LLV group
(44.2% vs 24.8%; p < 0.0001), nevertheless the median
IL-6 levels were slightly lower in the TND group than in
the LLV group, even if the difference was not statically
significant (TND: 14.5 pg/ml [IQR, 9.3–30.7]; LLV:
20.3 pg/ml [IQR, 14.3–33.1; p = 0.48) (Fig. 1b). A signifi-
cant correlation between IL-6 and TNF-α levels
(r = 0.50; p = 0.015) was found when the parameters
were detectable (23 out 321) (data not shown).
Marker of microbial translocation
To assess microbial translocation, the soluble form of
the LPS coreceptor CD14 (sCD14) was measured.
Ninety-seven percent of patients showed detectable
levels of sCD14. Significantly lower levels of sCD14 were
detected in the TND group (7.1 μg/ml [IQR, 6–8.9]) and
RV group (8.7 μg/ml [IQR, 6.8–11]) compared the LLV
group (10 μg/ml [IQR, 9–12.5], and a significant differ-
ence was detected between the TND and RV groups
(Fig. 1c). This difference persisted among groups after
adjusting for potential confounders such as gender, type
of antiretroviral regimen, cART duration, stage of dis-
ease, and years since diagnosis (Table 2).
HIV-DNA, VL pattern and inflammatory biomarkers
The association between total HIV-DNA and different de-
grees of viremia was investigated. Total HIV-DNA was
quantified in 90% of samples. When the HIV-DNA levels
were stratified on the basis of viremia, a significant differ-
ence among groups was observed. Specifically, HIV-DNA
load in PBMCs was higher in infected individuals with
LLV and RV than in patients with undetectable HIV-RNA













Age, y 53 [47–58] 52 [45–57] 54 [49–62] 53 [47–57]
Male (%) 217 (67) 75 (66) 78 (69) 64 (57)
Race/Ethnicity white/latino/other (%) 316 (98.5) 113 (100) 111 (98.2) 92 (97)
Black (%) 5 (1.5) 0 2.0 (1.8) 3.0 (3.0)
CD4 cells/mm3 601 [382–854] 641 [523–888] 565 [303–795] 565 [356–925] 0.017
Nadir CD4 cells/mm3 222 [108–366] 209 [112–362] 243 [108–327] 232 [107–409]
HIV infection, y 16 [10–22] 16 [13–21] 15 [8.0–20] 18 [10–22]
Duration of ART, y 15 [9.0–18.5] 15 [12–18] 13 [6.0–18] 18 [10–21]
HCV coinfection, n (%) 55 (17.1) 14 (12.4) 24 (21.2) 17 (17.9)
HBV coinfection, n (%) 17 (5.3) 6.0 (5.3) 4.0 (3.5) 7.0 (7.3)
Data are median [interquartile range] unless otherwise stated
aKruskal-Wallis tests
Abbreviations: TND target not detected, RV residual viremia, LLV low level viremia, ART antiretroviral therapy, HCV hepatitis C virus, HBV hepatitis B virus
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levels (LLV group: 3.05 log copies HIV-DNA /106 PBMC
[3.0–3.36] vs TND group: 2.59 log copies HIV-DNA /106
PBMC [2.25–2.88], p < 0.0001; RV group: 2.87 log copies
HIV-DNA /106 PBMC [2.53–3.18] vs TND, p = 0.001)
(Fig. 1d).
The association between HIV-DNA and residual viremia
was confirmed by logistic regression analysis (p = 0.003)
adjusting for age, sex, type of antiretroviral regimen, cART
duration, stage of disease, levels of TNF-α, IL-6, sCD14,
years since diagnosis, and risk of virological failure. To
verify whether the size of the HIV reservoir was associated
with different levels of inflammatory biomarkers (IL-6,
TNF-α and sCD14) regardless of viremia, a correlation
analysis performed on the overall population disclosed no
correlation between the size of blood HIV reservoir and
the biomarkers analyzed (data not shown).
Logistic regression analysis
Ordinal logistic analysis showed that two independent
variables were significantly associated with VL pattern:
sCD14 (OR 1.66, 95% CI 1.32–2.08; p < 0.001); HIV-
DNA (OR 1.01, 95% CI 1.00–1.02; p = 0.003); In addition
NRTIs + NNRTIs and NRTIs + PIs were negatively associ-
ated to VL pattern compared to INI-containing regimen
(Table 2).
Discussion
This study investigated the association between inflam-
matory and virological markers in HIV-infected patients
responding to therapy but with different VL patterns. To
our knowledge, this is one of the few studies to investi-
gate the relation between the size of the HIV reservoir,
VL and markers of inflammation in the same popula-
tion. The main findings were: 1. the link between
viremia and sCD14 levels; 2. the association between
viremia and HIV-DNA levels; 3. no link between HIV-
DNA and markers of inflammation; 4. no link between
HIV-RNA and IL-6 levels.
Our data in a large patient sample confirmed the link
between residual viremia and the size of viral reservoirs
[21–23]. However, whether residual replication is a cause
rather than an effect of higher HIV-DNA levels remains
to be established. All patients with sustained undetectable
viremia throughout the follow-up showed detectable levels
Fig. 1 Inflammatory markers and HIV-DNA levels in patients with different VL patterns. TNF-α (a), IL-6 (b), sCD14 (c) and intracellular HIV-DNA (d)
based on plasma VL pattern. TND (Target Not Detected): patients with a sustained undetectable viremia throughout follow-up; RV (Residual
Viremia): patients who had at least three detectable VL values but below the threshold value; LLV (Low Level Viremia): patients with at least two
VL values over the threshold value but below 200 copies/ml
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of HIV-DNA, strongly supporting the hypothesis that
most HIV-DNA is integrated in virologically controlled
patients. Because of the limited quantity of blood obtained
from patients, we could not perform assays aimed to de-
termine the frequency of cells carrying replication compe-
tent virus. Therefore we cannot exclude the possibility
that intracellular HIV-DNA in patients with maximum
viral suppression is mainly represented by defective latent
virus.
We also observed that TNF-α and sCD14 levels were
lower in patients with undetectable viremia than in indi-
viduals with residual/low level viremia. Previous findings
reported that sCD14 plasma levels in HIV-positive
patients were significantly higher than those in HIV-
negative subjects but were similar among HIV-positive
patients stratified according to plasma VL [25, 26]. A sig-
nificant difference from our study is that our population
was grouped according to their VL patterns. Patients
showing lower sCD14 levels had undetectable viremia
for at least 48 months and were compared with patients
who experienced either at least three low but detectable
levels of HIV RNA or at least two in the range of 37–
200 copies/mL. Therefore, a lack of maximal viral sup-
pression during follow-up seems to be associated with
higher level of sCD14. It is worth noting that although
patients with undetectable viremia had lower levels of
sCD14 than patients with residual/low level viremia, all
individuals showed detectable levels of this MT marker.
The lack of a control group in our study precluded a
comparison of results with data from healthy donors.
However, the normal range of sCD14 was given by the
manufacturer and was lower than the range detected in
the TND group. This supports previous findings [26, 27]
suggesting that residual viral replication contributes to
further increase the sCD14 level, but other mechanisms
such as a persistent alterations of monocytes-macrophage
function and a continuous microbial translocation favored
by persistent GALT-associated damage could maintain el-
evated sCD14 levels in virologically suppressed patients
[28, 29].
In our population, lower levels of TNF-α were also de-
tected in the TND group compared to patients with RV
and LLV. Although the difference among groups was
significantly different, the statistical power of this finding
is undermined by the low proportion of patients with
biomarker levels above the lower limit of detection. In-
deed, one of the limitations of our study is that we did
not use a high-sensitivity assay to measure inflammatory
markers, so the lowest levels of TNF-α were excluded by
the detection limit of the assay.
The lack of correlation between LLV and IL-6 is in
agreement with other studies reporting a direct correl-
ation between IL-6 levels and VL values above 400 cop-
ies/ml, suggesting that VL drives IL-6 production only at
high loads [30, 31].
The lack of association between IL-6 and viremia is
also consistent with findings previously reported by
Chun et al. who found that low levels viremia were not
statistically associated with IL-6 [21]. On the other hand,
Bastard and coworkers found an association between
HIV VL and IL-6, reporting that low-range IL-6 levels
correlated with low-range VL [12]. As explained above,
the low range of IL-6 in our study was excluded by the
detection limit and only high values of IL-6 were de-
tected. Despite this limitation, our data suggest that high
IL-6 levels are not affected by low levels of viremia. We
also observed a higher percentage of patients with IL-6
Table 2 Independent variables associated with viral load
pattern (TND, RV, LLV)
Variables ORa 95% CI pV
Gender
Male Ref. − −
Female 1.22 0.57–2.61 0.614
Age (years, continuous) 0.98 0.94–1.02 0.377
Therapy regimen
INI Ref. − −
NRTIs + NNRTIs 0.11 0.03–0.43 0.001
NRTIs + PIs 0.26 0.08–0.88 0.030
Others 0.22 0.05–0.95 0.043
Duration of therapy (years, continuous) 1.08 0.94–1.23 0.267
Stage of disease
A1-A3 Ref. − −
B1-B3 0.87 0.27–2.81 0.818
C1-C3 1.07 0.48–2.35 0.872
Years from testing (years, continuous) 0.96 0.85–1.08 0.494
HBV
Negative Ref. − −
Positive 2.25 0.67–7.59 0.191
HCV
Negative Ref. − −
Positive 0.77 0.23–2.54 0.664
sCD14 (continuous) 1.66 1.32–2.08 <0.001
IL-6 (continuous) 0.99 0.96–1.02 0.386
TNF-α (continuous) 1.03 0.95–1.10 0.519
HIV-DNA (continuous) 1.01 1.00–1.02 0.003
Abbreviations: INI integrase inhibitors, NRTIs nucleoside reverse transcriptase
inhibitors, NNRTIs non-nucleoside reverse transcriptase inhibitors, PIs protease
inhibitors, HCV hepatitis C virus, HBV Hepatitis B virus, sCD14 soluble CD14, IL-6
interleukin- 6, TNF-α tumor necrosis factor α
aProportional odds ratio. For example, concerning the variable “gender”, this is
the proportional odds ratio of comparing females to males on viral load
pattern level given that the other variables are held constant. For females, the
odds of LLV vs. combined RV and TND are 1.22 times greater than for males.
Likewise, the odds of the combined categories of LLV and RV vs. TND is 1.22
times greater for females compared to males, given the other variables are
held constant in the model
Falasca et al. BMC Infectious Diseases  (2017) 17:581 Page 5 of 7
levels above the LOD in the TND group than in the
others. This finding was somewhat unexpected, but sev-
eral factors other than the virus may contribute to the
inflammatory state seen during HIV infection. [32]. In-
deed high IL-6 levels were associated with higher body
mass index, smoking, comorbidities, renal function and
serum lipid levels, suggesting multiple determinants of
inflammation and/or IL-6 production during HIV infec-
tion. Our data support these findings, since the HIV sub-
jects enrolled in this study had been infected for a long
time, had a long therapeutic history and most of them
showed other comorbidities, such as coinfections, car-
diovascular diseases, renal disease or tumors.
We also evaluated the possibility that HIV-DNA levels
could be correlated with inflammatory markers such as
sCD14 and IL-6, but no correlation was found between
the size of the blood reservoir and sCD14 or IL-6. This
data is in agreement with other findings reporting no as-
sociation between intracellular HIV-DNA levels and in-
flammatory biomarkers such as IL-6, C-reaction protein,
soluble TNF receptor I and immune activation markers
on CD4+ and CD8 + T cells [21, 24] in ART-treated pa-
tients. Interestingly, a strong positive correlation be-
tween HIV-DNA and CD8+ T cell activation was found
in viremic patients with primary or chronic infection,
whereas there was no correlation between T-cell activa-
tion and HIV-DNA in patients with successfully treated
chronic infection [33]. In this framework, our data con-
firm that inflammation is not directly associated with
the size of the HIV reservoir and emphasize the role of
other factors in maintaining elevated levels of immune
activation in ART-treated subjects.
Finally and unexpectedly, we observed that patients
with low level viremia were more likely to be treated
with INIs. Indeed, about half of patients with LLV,
treated with a cART containing INI, were treated with a
therapy combined with PIs, therefore we cannot rule out
the possibility that the above association could be mainly
due to the simultaneous usage of both drugs. However,
since the remaining patients were treated with INIs
combined with different drugs we believe that this result
may be due to a selection bias, since patients starting
therapeutic regimen containing integrase inhibitor, were
mostly represented by patients with more previous treat-
ment failures and with a history of non-adherence to
ART. The same consideration could explain, at least in
part, the discrepancy of our finding with the literature
data reporting that PIs containing regimens increase the
risk to have LLV [34, 35].
The study has some limitations. We evaluated only
three biomarkers and hence cannot rule out the possibility
that other inflammatory parameters might have provided
useful information. However we chose three markers as-
sociated with disease progression and reported to be
predictors of clinical events and mortality during HIV in-
fection [14, 36–40]. Our analysis did not have multiple
longitudinal measures of inflammatory markers or HIV-
DNA, so we could not investigate the change in these
markers over time or their relation with the VL value.
Conclusion
In summary, our results confirm that a full viral sup-
pression is associated with both a smaller HIV reservoir
and lower sCD14 levels, emphasizing the need to main-
tain VL at undetectable levels. However the lack of
normalization of inflammatory markers in patients with
persistent undetectable viremia and the fact that HIV-
DNA load was not associated with inflammation
strongly suggests that HIV infection triggers inflamma-
tion, but other mechanisms play a major role in main-
taining the inflammatory status over time.
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